The CIS market for insulin and insulin products is expected to reach USD 3,008.5 million by 2020 growing at a CAGR of 15.0%. The presence of an extensive pipeline portfolio of products exhibiting higher efficacies and their subsequent commercialization over the next six years is expected to serve this market as a high impact rendering driver. The introduction of government initiatives aimed at improving the affordability of insulin via price reduction, such as the collaboration between the government of Ukraine and Indar to reduce the price of insulin by 20% in 2013 is expected to have positive influence on demand. Some of the other drivers of this market include increasing attempts made by manufacturers to capitalize on the untapped opportunities by opening new manufacturing units to improve the supply of insulin and growing incidence rates of type II diabetes are some of the factors expected to fuel future market growth.
Further Key findings from the study suggest:
Regionally, Russia occupied the largest share of the market, accounting for 69.2% of the revenue. Its large share is majorly attributed by the subsidies that Russian government provides to make insulin more affordable for patients.
Ukraine is expected to register the fastest CAGR of 15.6% during the forecast period due to the presence of high untapped opportunities and encouraging government initiatives.
In addition, Poland is expected to grow at a lucrative rate during the forecast period majorly owing to the presence of high diabetes prevalence coupled with increasing healthcare expenditures.
Long acting insulin accounted for the largest share of the market, at over 39.0% in 2013, owing to the higher preference given to long acting insulin therapy for diabetes which results in lesser episodes of low blood sugar. It is also expected that this product segment will grow at the fastest CAGR of over 18.0% during the next six years.
Application of insulin for control of type II diabetes occupied for over 90.0% of the market owing to the presence of larger portfolio of products catering to this segment and a relatively larger prevalence base
Analogs accounted for over 80.0% of the revenue owing to their relatively higher prices and better efficacy levels. In addition, this segment is expected to exhibit the fastest CAGR during the forecast period on account of the introduction of technologically advanced products such as ultra-long and ultra-fast acting analogs.
For the purpose of this study, Grand View Research has segmented the CIS Insulin market on the basis of product, application, source and region:
- CIS Insulin Product Outlook - Rapid Acting - Long Acting - Premixed - Premixed Analog - Short Acting - Intermediate Acting - CIS Insulin Application Outlook - Type II Diabetes - Type I Diabetes - CIS Insulin Source Outlook - Human Recombinant - Analogs - CIS Insulin Regional Outlook - Russia - Poland - Turkey - Ukraine - Uzbekistan - Belarus - Kazakhstan - Rest of CIS
Our reports have been used by over 10K customers, including:
Hypoglycemia (Metabolic Disorder) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Hypoglycemia - Drugs in Development, 2021, provides an overview of the Hypoglycemia (Metabolic Disorders) pipeline landscape. Hypoglycemia is a condition...
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drugs in Development, 2021 Summary Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) pipeline Target constitutes close to 17 molecules. Out...
The peptide therapeutics market was valued at US$ 24,878.55 million in 2019 and is projected to reach US$ 50,003.15 million by 2027; it is expected to grow at a CAGR of 9.2% during 2020–2027. The growth of the peptide therapeutics market is mainly attributed to the growing investments on peptide therapeutics and increasing prevalence of metabolic...
‘Diabetic Foot Ulcer (DFU) - Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the DFU, historical and forecasted epidemiology as well as the DFU market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.
The DFU market report provides current...
The South & Central America closed systems drug transfer devices market is expected to reach US$ 118.49 million by 2027 from US$ 28.37 million in 2019; it is estimated to grow at a CAGR of 19.6% from 2020 to 2027. The closed systems drug transfer devices market in South & Central America is primarily driven by rise in adoption of chemotherapy...
The global autoinjectors market is projected to reach USD 104.9 billion by 2025 from USD 46.0 billion in 2020, at a CAGR of 17.9% from 2020 to 2025. Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages,...
Insulin Resistance Pipeline Overview
The Q4 Insulin Resistance pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of drugs under development for Insulin Resistance, provides an update on the mechanism of action and targets, licensing and collaboration...
Glucokinase - Pipeline Review, H2 2020
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 126.96.36.199) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Glucokinase...
The market is expected to reach US$ 11,614.32 million in 2027 from US$ 9,106.40 million in 2019. The market is estimated to grow with a CAGR of 3.2% from 2020-2027. The growth of the market is attributed to some key driving factors such as growing prevalence of urinary tract infections, aging population and emerging computing technologies...
The biofilms treatment market was valued at US$ 1,590.31 million in 2019 and is projected to reach US$ 2,825.80 million by 2027; it is expected to grow at a CAGR of 7.5% during 2020–2027. The increasing incidence of wounds and ulcers, and growing number of surgical procedures across the world fuel the market growth. Moreover, continuous innovations...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.